PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

Continued strong financial results and cash generation, achieving all 2025 guidance metrics Full year earnings growth; GAAP ...

ADT Inc. (NYSE: ADT) will release Q4 earnings on March 2. Analysts expect 22 cents per share, up from 20 cents last year.

Discover the top 4 undervalued Diversified Consumer Services stocks for Thursday, February 26 based on AAII’s Stock Grades.